Hepatitis B, C seroprevalence and delta viruses in HIV‐1 Senegalese patients at HAART initiation (retrospective study)

Abstract

The aim of this study was to determine hepatitis co-infection in a cohort of HIV infected patients at their inclusion in the Senegalese Initiative of ART Access. B, C, and D Hepatitis viruses serological markers were checked retrospectively on 363 stored plasma. For HBV, the Abbott laboratories equipment IMx was used to detect HBs Ag and anti Core Ab on negative HBs Ag samples. For HDV, anti Delta Ab was performed using the Abbott Murex Kit on all HBs Ag positive samples. For HCV, anti HCV Ab was detected by IMx as double screening test and confirmed by INNO-LIA(TM) HCV Core of Innogenetics laboratories. The statistical analysis was done with STATA V8. The study population was composed of 164 men and 199 women aged between 16 and 66 years. The immune and virological markers averages at their enrollment were 154 cell/mm(3) for TLCD4+ (n = 355 patients) and 4.9 log for viral load (n = 277 patients). HBs Ag was found in 61 patients or 16.8% and the prevalence of anti-HBc Ab was 83.2% (252/295). 2 patients or 3% on HBs Ag positive sample presents HBV/HDV co-infection Ab anti HCV was detects in 6 patients or 1.6% after confirmation and 2 patients had triple infection with HBV. These results showed that the prevalence of HBV and HCV in the population of persons living with HIV/AIDS in Senegal is similar to that found in the general population. Our data indicated that hepatitis pathology in the PLwHIV was essentially due to HBV. Further studies are needed to diagnose occult hepatitis in order to set up therapeutic strategies taking into account co-infections by hepatitis viruses in the ART programmes.

Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients

“…Our study results confirm the high prevalence of HBV infection among HIV patients in Côte d'Ivoire, and more generally in sub-Saharan Africa, as evidenced by most studies on the subject [10,13,[15][16][17][18][19][20][21][22] . Indeed, the prevalence of HBsAg and that of anti-HBcAb were respectively 13.4% and 72.9% in our patients.…”

Anti-HCV antibody among newly diagnosed HIV patients in Ughelli, a suburban area of Delta State Nigeria

“…This figure is much lower than the figure obtained in our study (15.0%) (Figure 1). Our figure is also higher than what was obtained in similar studies in Kenya, East Africa (10.0%), Senegal, West Africa (1.6%) and South Africa (13.4%) [36][37][38] but lower than that of another Eastern Africa state, Tanzania (18.1%) 39 . The difference in prevalence could be due to differences in social behaviour of the individuals involved in this study and population size of the individual countries 40 …”

Epidemiological and Evolutionary Profile of HIV-HBV Co-Infected Patients Followed at Ambulatory Treatment Center in Fann Hospital Dakar-Senegal

“…This is obviously lower than the (16.8%) prevalence found by H. Ndiaye-Diop et al in Dakar in 2008(Diop-Ndiaye et al, 2008, but similar to the prevalence found by Lô et al, in 2012(Lô et al, 2012) (11%) among pregnant women living with HIV in Senegal. This decrease in seroprevalence could be explained by the effectiveness of vaccination against viral hepatitis B in Senegal and the systematic search for HBsAg in the assessment at prenatal consultations.…”

“…This is higher than the average found in available sources: 34 years in the study of Chloe L. Thio et al (Thio et al, 2013), 36 years in that of Attia et al (Attia et al, 2012), 32 years in that realized by Yitayih M. et al (Yitayih, Meseret, Fanaye, & Yeshambel, 2013), 38 years in the work of H. Diop-Ndiaye et al (Diop-Ndiaye et al, 2008). This could be explained by the youth of the overall African population but also by the fact that the population is sexually active at this age.…”